NCT06955169 2026-04-16
MOMENTUM-1
RTOG Foundation, Inc.
Phase 2 Recruiting
Clinical Trials
27 trialsNCT00814021 2026-04-15
Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
Institut Claudius Regaud
Phase 2 Completed
NCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06326190 2025-09-16
LUMEN-1
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Recruiting
NCT00843037 2024-10-17
SNIPP
University Health Network, Toronto
Phase 2 Completed
NCT00981890 2022-10-07
Stereotactic Radiosurgery With Sunitinib for Brain Metastases
University Health Network, Toronto
Phase 1 Completed
NCT01371201 2022-08-04
FIRSTMAPPP
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT03641326 2022-04-19
Sunitinib in Sarcomas of the Central Nervous System
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT03025893 2021-04-19
STELLAR
Amsterdam UMC, location VUmc
Phase 2/3 Unknown
NCT02239952 2020-10-08
HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)
Amsterdam UMC, location VUmc
Phase NA Unknown
NCT03275558 2018-07-19
Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma
Center Trials & Treatment
Phase 1 Withdrawn
NCT02928575 2016-10-10
Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase 2 Unknown
NCT00864864 2016-07-07
Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma
Massachusetts General Hospital
Phase EARLY_PHASE1 Completed
NCT00499473 2016-02-29
Sunitinib in Treating Patients With Recurrent Malignant Gliomas
National Cancer Institute (NCI)
Phase 2 Completed
NCT00589784 2016-01-25
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00462982 2015-12-30
Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00923117 2015-09-30
Sunitinib to Treat Recurrent Brain Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01462695 2015-08-27
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00910039 2014-09-29
Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT00570908 2014-09-18
Brain Mets - Capecitabine Plus Sunitinib and WBRT
Baylor Breast Care Center
Phase 2 Terminated
NCT00611728 2014-07-21
Ph I SU011248 + Irinotecan in Treatment of Pts w MG
Duke University
Phase 1 Completed
NCT00387920 2014-01-28
Sunitinib in Treating Young Patients With Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT01100177 2013-03-11
Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients
Grupo Español de Investigación en Neurooncología
Phase 2 Completed
NCT00606008 2012-11-19
A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01441388 2011-12-20
A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
Pfizer
Phase 1 Withdrawn
NCT00372775 2011-02-24
Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases
Pfizer
Phase 2 Completed
NCT00535379 2010-08-30
SURGE01-07
Medical University Innsbruck
Phase 2 Unknown